Two Sigma Advisers
MBRX icon

Two Sigma Advisers’s Moleculin Biotech MBRX Stock Holding History

Two Sigma Advisers’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31
Closed -$17K – 2662
2022
Q2 		$17K Sell
31
-34
-52% -$19.8K ﹤0.01% 2562
2022
Q1 		$43K Buy
65
+16
+33% +$9.17K ﹤0.01% 2603
2021
Q4 		$34K Buy
+49
New +$43.5K ﹤0.01% 2513

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers's MBRX Position: Q3 2022 in Review

Two Sigma Advisers sold out of Moleculin Biotech (MBRX) in Q3 2022, closing a stake of 31 shares — an estimated $17K sold.

Two Sigma Advisers first reported a position in MBRX in Q4 2021 and held it in 3 quarters. The position peaked at $43K in Q1 2022. 24 funds tracked by Wall St. Rank hold MBRX as of Q3 2022.

  • Two Sigma Advisers reported no remaining Moleculin Biotech position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 31 Moleculin Biotech shares in Q3 2022, an estimated $17K.
  • Two Sigma Advisers first reported a position in Moleculin Biotech in Q4 2021 and held it in 3 quarters.
  • Two Sigma Advisers's Moleculin Biotech position peaked at $43K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.